BMY

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -1.27
Percentage change -2.11	%

Peers: PFE JNJ MRK LLY ABBV GILD AMGN AZN NVS

| Held by: VTI VOO SCHD SPY IVV VTV XLV JEPI COWZ VYM

Index	S&P 500	P/E	-	EPS (ttm)	-4.43	Insider Own	0.08%	Shs Outstand	2.03B	Perf Week	-3.40%
Market Cap	119.75B	Forward P/E	9.63	EPS next Y	6.13	Insider Trans	0.31%	Shs Float	2.03B	Perf Month	5.09%
Income	-8948.00M	PEG	-	EPS next Q	1.52	Inst Own	79.99%	Short Float	1.51%	Perf Quarter	1.53%
Sales	48.30B	P/S	2.48	EPS this Y	486.75%	Inst Trans	3.15%	Short Ratio	2.57	Perf Half Y	21.44%
Book/sh	8.05	P/B	7.33	EPS next Y	-9.20%	ROA	-9.53%	Short Interest	30.57M	Perf Year	8.47%
Cash/sh	5.35	P/C	11.03	EPS next 5Y	73.99%	ROE	-39.10%	52W Range	39.35 - 63.33	Perf YTD	4.33%
Dividend Est.	2.46 (4.17%)	P/FCF	8.59	EPS past 5Y	-	ROI	-13.70%	52W High	-6.82%	Beta	0.41
Dividend TTM	2.42 (4.10%)	Quick Ratio	1.15	Sales past 5Y	18.97%	Gross Margin	56.80%	52W Low	49.96%	ATR (14)	1.60
Dividend Ex-Date	Apr 04, 2025	Current Ratio	1.25	EPS Y/Y TTM	-214.24%	Oper. Margin	18.51%	RSI (14)	50.45	Volatility	2.69% 2.61%
Employees	34100	Debt/Eq	3.13	Sales Y/Y TTM	7.32%	Profit Margin	-18.53%	Recom	2.56	Target Price	60.68
Option/Short	Yes / Yes	LT Debt/Eq	3.00	EPS Q/Q	-95.92%	Payout	59.82%	Rel Volume	1.00	Prev Close	60.28
Sales Surprise	6.70%	EPS Surprise	14.13%	Sales Q/Q	7.54%	Earnings	Feb 06 BMO	Avg Volume	11.88M	Price	59.01
SMA20	0.79%	SMA50	1.98%	SMA200	13.82%	Trades		Volume	11,894,296	Change	-2.11%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-16-24	Upgrade	Jefferies	Hold → Buy	$70
Dec-10-24	Resumed	BofA Securities	Neutral	$63
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-13-24	Upgrade	Daiwa Securities	Neutral → Outperform
Nov-12-24	Upgrade	Leerink Partners	Market Perform → Outperform	$73
Oct-25-24	Downgrade	Citigroup	Buy → Neutral	$75 → $55
Oct-17-24	Initiated	Bernstein	Mkt Perform	$56
Jul-29-24	Downgrade	Barclays	Overweight → Equal Weight	$41
Mar-11-24	Downgrade	Societe Generale	Buy → Hold
Feb-06-24	Downgrade	Redburn Atlantic	Buy → Neutral	$77 → $54
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral	$68 → $60
Nov-15-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$68 → $55
Nov-09-23	Initiated	Deutsche Bank	Hold	$55
Nov-02-23	Downgrade	Daiwa Securities	Outperform → Neutral	$68 → $54
Oct-27-23	Upgrade	HSBC Securities	Reduce → Hold	$55 → $53
Oct-27-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-27-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$60
Oct-20-23	Resumed	UBS	Neutral	$70 → $60
Jul-14-23	Initiated	HSBC Securities	Reduce	$56
Jul-10-23	Initiated	SVB Securities	Market Perform	$66

Show Previous Ratings

Mar-14-25 06:59AM	Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma (Business Wire)
05:30AM	Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. (The Wall Street Journal)
Mar-13-25 06:59AM	Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025 (Business Wire)
Mar-10-25 10:17PM	2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb (Business Wire)
08:13PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
04:30PM	Loading…
04:30PM	Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out (Investor's Business Daily)
Mar-08-25 02:20PM	Is Bristol-Myers Squibb Company (BMY) The Best Cheap Dividend Stock To Buy Right Now? (Insider Monkey)
09:01AM	Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis (Business Wire)
Mar-07-25 06:59AM	Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma (Business Wire)
Mar-03-25 04:16PM	Bristol Myers Squibb Announces Dividend (Business Wire)
Feb-28-25 07:00AM	Drug Stocks Are the New Safe Bet in a Shaky Market (The Wall Street Journal)
Feb-26-25 02:25PM	Bristol-Myers Squibb Company (BMY): Top Stock to Buy from Dividend Stock Portfolio For Income (Insider Monkey)
Feb-25-25 06:59AM	Bristol Myers Squibb to Participate in Upcoming Investor Conferences (Business Wire)
Feb-24-25 06:59AM	U.S. Food and Drug Administration Accepts Bristol Myers Squibbs Supplemental Biologics License Application for Opdivo Plus Yervoy for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient... (Business Wire)
Feb-19-25 06:59AM	Bristol Myers Squibb Announces Opdivo Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer (Business Wire)
10:05AM	Loading…
Feb-18-25 10:05AM	Bristol Myers announces new five-year results from POETYK PSO trial (TipRanks)
Feb-17-25 02:51AM	Why Bristol-Myers Squibb (BMY) Is Among the Best Drug Stocks to Buy Now (Insider Monkey)
Feb-16-25 06:59AM	New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis (Business Wire)
Feb-13-25 04:16PM	Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial (Business Wire)
Feb-11-25 05:30AM	The Magnificent 7 Are So Last Year. Cash Cows Are the New Kings. (The Wall Street Journal)
Feb-10-25 06:59AM	Bristol Myers Squibb Announces Positive Topline Results for Breyanzi (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma (Business Wire)
Feb-06-25 08:48PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
05:03PM	Bristol-Myers Squibb stock in focus on weak outlook (Yahoo Finance Video)
04:03PM	Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook (Investor's Business Daily)
11:27AM	Eli Lilly, Bristol Myers Squibb, Peloton: Market Minute (Yahoo Finance Video)
06:59AM	Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024 (Business Wire)
Feb-04-25 09:50AM	Pfizer beats Q4, FY '24 earnings estimates, stock flat in early trading (Yahoo Finance)
08:52AM	Pfizer beats Q4, FY '24 earnings estimates, stock flat in premarket trading (Yahoo Finance)
08:52AM	Pfizer beats Q4, FY '24 earnings estimates, stock down slightly in premarket trading (Yahoo Finance)
Feb-01-25 08:00AM	No One Knows How to Price AI Tools (The Wall Street Journal)
04:01PM	Loading…
Jan-31-25 04:01PM	Top Dividend Stocks Yielding As High As 5%: Fidelity (Investor's Business Daily)
06:59AM	Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma (Business Wire)
06:50AM	Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma (Business Wire)
Jan-29-25 10:12PM	Why Bristol-Myers Squibb Company (BMY) Is the Best Blue Chip Stock to Buy Under $100? (Insider Monkey)
03:50PM	Bristol-Myers Squibb (BMY): Cramer's Old-School Move for DeepSeek Market Jitters (Insider Monkey)
Jan-28-25 03:00PM	Drugmakers Show Restraint on Price Increases in New Trump Era (The Wall Street Journal)
Jan-25-25 10:02AM	Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) Compared to Opdivo Monotherapy... (Business Wire)
Jan-18-25 05:01PM	Why Bristol-Myers Squibb (BMY) Is One of the Best Cheap Stocks to Buy for 2025? (Insider Monkey)
08:20AM	Ozempic, Xtandi among next 15 drugs selected for U.S. price talks (TipRanks)
Jan-17-25 11:10AM	Ozempic Among the Next Drugs Up for Medicare Price Negotiations (The Wall Street Journal)
09:46AM	Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations (Yahoo Finance)
Jan-13-25 03:13PM	Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal (The Wall Street Journal)
07:00AM	ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors (GlobeNewswire)
Jan-10-25 12:50PM	Bristol Myers Squibb Named to Dow Jones Sustainability Index North America for Second Consecutive Year (ACCESSWIRE)
08:30AM	AI, vaccine distrust, & the future of healthcare: Novartis CEO (Yahoo Finance Video)
Jan-06-25 09:00AM	LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer (Business Wire)
Jan-03-25 06:59AM	Bristol Myers Squibb to Present at J.P. Morgans 43rd Annual Healthcare Conference (Business Wire)
Dec-31-24 01:14PM	Is Bristol-Myers Squibb Company (BMY) Among the Best Pharma Dividend Stocks to Buy In 2024? (Insider Monkey)
Dec-30-24 02:14PM	Is Bristol-Myers Squibb Co. (BMY) the Best Stock for 10 Years? (Insider Monkey)
Dec-27-24 05:37PM	U.S. Food and Drug Administration Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo (nivolumab) Indications1,2 (Business Wire)
Dec-23-24 06:59AM	Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis (Business Wire)
06:45AM	Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite InstabilityHigh or Mismatch Repair Deficient Metastatic Colorectal Cancer (Business Wire)
Dec-19-24 02:28PM	Bristol Myers Squibb Stock Earns 83 RS Rating (Investor's Business Daily)
06:59AM	Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025 (Business Wire)
01:48AM	BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program (PR Newswire)
Dec-18-24 09:00AM	insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS (Business Wire)
08:45AM	Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic and Anal Cancers (GlobeNewswire)
Dec-17-24 06:30AM	Bristol Myers upgraded to Buy at Jefferies on new launch momentum, pipeline (TipRanks)
Dec-11-24 04:17PM	Bristol Myers Squibb Announces Dividend Increase (Business Wire)
Dec-09-24 05:45PM	Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline (Business Wire)
Dec-07-24 05:30AM	Dividend Stocks Are Primed for a Comeback in 2025 (The Wall Street Journal)
Dec-03-24 08:00AM	AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M (Business Wire)
Dec-02-24 07:44AM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
Nov-26-24 06:59AM	Bristol Myers Squibb to Participate in Citis 2024 Global Healthcare Conference (Business Wire)
Nov-22-24 04:09PM	AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback (Investor's Business Daily)
11:30AM	AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback (Investor's Business Daily)
Nov-19-24 06:59AM	Bristol Myers Squibbs Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms (Business Wire)
Nov-18-24 07:30AM	Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer (Newsfile)
12:41AM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
Nov-15-24 07:22PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
08:23AM	Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite InstabilityHigh or Mismatch Repair Deficient Metastatic Colorectal Cancer (Business Wire)
06:59AM	Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors (Business Wire)
Nov-13-24 04:07PM	Avidity Bio Has Surged 416% This Year And That's Before Today's 'Game-Changing' News (Investor's Business Daily)
Nov-12-24 04:05PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results (GlobeNewswire)
07:00AM	What the NFL Draft Can Teach Investors About Big Pharma (The Wall Street Journal)
Nov-11-24 07:00PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research) +10.49%
04:32PM	S&P 500 Gains and Losses Today: Index Closes Above 6,000 on Post-Election Rally (Investopedia)
04:04PM	Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake' (Investor's Business Daily)
03:45PM	AbbVie tumbles on drug test disappointment, Bristol-Myers gains (Yahoo Finance Video)
10:12AM	Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails (Investor's Business Daily)
09:39AM	AbbVie Stock Slides on Schizophrenia Drug Study Failure (The Wall Street Journal)
06:59AM	Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024 (Business Wire)
Nov-08-24 09:34AM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
Nov-05-24 05:00PM	Bristol Myers Squibb to Participate in Upcoming Investor Conferences (Business Wire)
Nov-01-24 03:07PM	Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade (Investor's Business Daily)
Oct-31-24 04:16PM	Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024 (Business Wire) +5.91%
04:12PM	Bristol Myers Screams To A Year-High After Walloping Profit Expectations (Investor's Business Daily)
02:43PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
10:03AM	Bristol Myers Squibb stock rises, Merck moves lower. Here's why. (Yahoo Finance Video)
07:12AM	Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance (Investor's Business Daily)
06:59AM	Bristol Myers Squibb Reports Third Quarter Financial Results for 2024 (Business Wire)
Oct-29-24 11:17AM	Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure (Yahoo Finance)
Oct-28-24 06:59AM	Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024 (Business Wire)
Oct-26-24 07:00AM	Pfizers Activist Battle Might Fizzlebut Its Stock Probably Wont (The Wall Street Journal)
Oct-16-24 04:21PM	Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. (Investor's Business Daily)
Oct-15-24 06:09PM	Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment (Investor's Business Daily)
Oct-14-24 09:59PM	Jim Cramer on Bristol-Myers Squibb Company (BMY): 'I Think It's A Great Time To Consider Buying This One' (Insider Monkey)
Oct-07-24 05:30AM	Old Drug Repurposed for Schizophrenia Could Reap Alzheimers Windfall (The Wall Street Journal)
Oct-03-24 05:35PM	U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC) (Business Wire)
01:11PM	Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear (Investor's Business Daily)

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Plenge Robert M	EVP, Chief Research Officer	Mar 10 '25	Option Exercise	0.00	11,255	0	20,148	Mar 12 09:39 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Mar 10 '25	Option Exercise	0.00	23,150	0	26,937	Mar 12 09:37 PM
Shanahan Karin	EVP, Glob. Prod. Dev. & Supply	Mar 10 '25	Option Exercise	0.00	20,423	0	22,339	Mar 12 09:35 PM
Lenkowsky Adam	EVP, Chief Commercial Officer	Mar 10 '25	Option Exercise	0.00	16,684	0	20,017	Mar 12 09:34 PM
Poole Ahn Amanda	EVP, Chief People Officer	Mar 10 '25	Option Exercise	0.00	7,164	0	8,546	Mar 12 09:32 PM
LEUNG SANDRA	EVP, General Counsel	Mar 10 '25	Option Exercise	0.00	48,718	0	386,496	Mar 12 09:32 PM
Hoch Lynelle	President, Cell Therapy Org.	Mar 10 '25	Option Exercise	0.00	7,446	0	7,920	Mar 12 09:31 PM
Holzer Phil M	SVP and Controller	Mar 10 '25	Option Exercise	0.00	7,140	0	17,870	Mar 12 09:31 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Mar 10 '25	Option Exercise	0.00	44,098	0	99,040	Mar 12 09:30 PM
Gallman Cari	EVP, Corporate Affairs	Mar 10 '25	Option Exercise	0.00	7,588	0	11,626	Mar 12 09:29 PM
Elkins David V	EVP, Chief Financial Officer	Mar 10 '25	Option Exercise	0.00	69,517	0	252,608	Mar 12 09:28 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Mar 10 '25	Option Exercise	0.00	60,034	0	152,898	Mar 12 09:27 PM
Hickey Benjamin	President, RayzeBio Org.	Mar 01 '25	Option Exercise	0.00	3,286	0	10,419	Mar 04 05:44 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Feb 20 '25	Buy	55.05	2,000	110,096	104,626	Feb 21 07:09 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Feb 14 '25	Buy	54.84	1,823	100,000	63,932	Feb 19 07:19 PM
Hickey Benjamin	President, RayzeBio Org.	Feb 01 '25	Option Exercise	0.00	10,078	0	10,858	Feb 04 07:05 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Feb 01 '25	Option Exercise	0.00	2,543	0	7,829	Feb 04 07:04 PM
Holzer Phil M	SVP and Controller	Nov 04 '24	Sale	55.62	700	38,930	11,760	Nov 05 05:53 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Nov 01 '24	Option Exercise	0.00	2,964	0	104,169	Nov 05 05:42 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Nov 01 '24	Buy	54.67	1,830	100,055	62,109	Nov 05 05:41 PM
Holzer Phil M	Officer	Nov 04 '24	Proposed Sale	55.62	700	38,930		Nov 04 11:20 AM
Gallman Cari	EVP, Corporate Affairs	Oct 02 '24	Option Exercise	0.00	4,558	0	6,667	Oct 03 06:33 PM
Gallman Cari	EVP, Corporate Affairs	Aug 01 '24	Option Exercise	0.00	1,061	0	2,493	Aug 05 06:01 PM
Shanahan Karin	EVP, Glob. Prod. Dev. & Supply	Apr 01 '24	Option Exercise	0.00	3,306	0	6,532	Apr 02 06:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Bristol-Myers Squibb Co

Upgrade your FINVIZ experience